ArticleActa neuropathologica2020
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
Abstract read
In one paragraph
Article in Acta neuropathologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 292 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
292citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
292 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Homozygous CDKN2A/B deletions in low- and high-grade glioma: a meta-analysis of individual patient data and predictive values of p16 immunohistochemistry testing.Acta neuropathologica communications · 2024Pooled it
- Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.International journal of clinical oncology · 2024Guideline
- Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults.Journal of neuro-oncology · 2022Pooled it
- Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.Neuropathology and applied neurobiology · 2022Pooled it
- Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.Archives of pathology & laboratory medicine · 2022Guideline
- Machine Learning Models for Classifying High- and Low-Grade Gliomas: A Systematic Review and Quality of Reporting Analysis.Frontiers in oncology · 2022Pooled it
- STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma.International journal of radiation oncology, biology, physics · 2025Trial
- The clinical and molecular landscape of thalamic glioma.Neuro-oncology · 2026Article
- Imaging diagnosis of adult-type diffuse gliomas in the era of WHO CNS5 and cIMPACT-NOW updates 8-11: a narrative review.Japanese journal of radiology · 2026Review
- Artificial intelligence-based diagnostic model for identifying PTPRZ1-MET fusion in a clinically defined secondary glioblastoma cohort.Molecular biomedicine · 2026Article
- Expanding the molecular grading criteria in IDH-mutant astrocytoma.Neuro-oncology · 2026Article
- Real-World Validation of the Clinical Distinctiveness of IDH-Mutant Glioblastoma in the SEER Transition Era: A Population-Based Study Integrating Machine Learning.Brain and behavior · 2026Article
- Validation of proposed cIMPACT-NOW update 12 molecular grading criteria for IDH-mutant astrocytoma.Acta neuropathologica · 2026Article
- Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management.Current treatment options in oncology · 2026Review
- Article
- Integrated transcriptomic analysis reveals KRAS-associated gene activation and epigenetic regulation in mutant IDH1 glioma.Genes & genomics · 2026Article
- Utility of digital PCR for detecting TERT promoter mutations and CDKN2A homozygous deletion in meningioma.Brain tumor pathology · 2026Article
- T2Pdecoder enables protein-centric analyses from transcriptomic data.Nature communications · 2026Article
- Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Asia-Pacific journal of clinical oncology · 2026Review
232 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Daniel J BratDepartment of Pathology, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Ward Building, 3-140, 303 E. Chicago Ave, Chicago, IL, 60611, USA. Daniel.brat@northwestern.edu.
Kenneth AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Howard ColmanDepartment of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Dominique Figrarella-BrangerService d'Anatomie Pathologique et de Neuropathologie, Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Marseille, France.
Gregory N FullerDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Caterina GianniniDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Eric C HollandDivision of Human Biology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Bette Kleinschmidt-DeMastersDepartment of Pathology, University of Colorado School of Medicine, Aurora, CO, USA.
Takashi KomoriDepartment of Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.
Johan M KrosDepartment of Pathology, Erasmus Medical Center, Rotterdam, Netherlands.
David N LouisDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Catriona McLeanAlfred Anatomical Pathology and NNF, Victorian Brain Bank, Carlton, VIC, Australia.
Arie PerryDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Guido ReifenbergerDepartment of Neuropathology, Heinrich Heine University, Düsseldorf, Germany.
Chitra SarkarDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Roger StuppRobert H. Lurie Cancer Center, Malnati Brain Tumor Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Martin J van den BentDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Andreas von DeimlingDepartment of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
Michael WellerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Funding
Genomic Biomarkers of CancerZIABC011850 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALDAPE, KENNETH · 2019 to 2025
$5.1MIdentification and targeting of mechanisms specific to glioma stem cells in glioblastomaR01CA214928 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BRAT, DANIEL J · 2018 to 2022
$1.8MIntramural NIH HHS ZIA BC011850NCI NIH HHS R01 CA214928
Abstract
PubMed holds no abstract for this paper.
Indexed as
AstrocytomaBrain NeoplasmsHumansIsocitrate DehydrogenaseMutationNeoplasm GradingTerminology as TopicWorld Health OrganizationIDH1 protein, humanIsocitrate Dehydrogenase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.